ArriVent BioPharma (AVBP) Competitors $22.03 -1.58 (-6.69%) Closing price 03/3/2025 04:00 PM EasternExtended Trading$22.05 +0.02 (+0.09%) As of 03/3/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends AVBP vs. RYTM, VKTX, ACAD, MRUS, MTSR, DNLI, XENE, MOR, HCM, and BHCShould you be buying ArriVent BioPharma stock or one of its competitors? The main competitors of ArriVent BioPharma include Rhythm Pharmaceuticals (RYTM), Viking Therapeutics (VKTX), ACADIA Pharmaceuticals (ACAD), Merus (MRUS), Metsera (MTSR), Denali Therapeutics (DNLI), Xenon Pharmaceuticals (XENE), MorphoSys (MOR), HUTCHMED (HCM), and Bausch Health Companies (BHC). These companies are all part of the "pharmaceutical products" industry. ArriVent BioPharma vs. Rhythm Pharmaceuticals Viking Therapeutics ACADIA Pharmaceuticals Merus Metsera Denali Therapeutics Xenon Pharmaceuticals MorphoSys HUTCHMED Bausch Health Companies Rhythm Pharmaceuticals (NASDAQ:RYTM) and ArriVent BioPharma (NASDAQ:AVBP) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, community ranking, earnings, risk, institutional ownership, profitability and dividends. Which has preferable valuation and earnings, RYTM or AVBP? ArriVent BioPharma has lower revenue, but higher earnings than Rhythm Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRhythm Pharmaceuticals$130.13M24.75-$184.68M-$4.35-12.05ArriVent BioPharmaN/AN/A-$69.33MN/AN/A Is RYTM or AVBP more profitable? ArriVent BioPharma has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -230.07%. ArriVent BioPharma's return on equity of -43.89% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rhythm Pharmaceuticals-230.07% -367.36% -77.47% ArriVent BioPharma N/A -43.89%-29.67% Do institutionals & insiders believe in RYTM or AVBP? 9.5% of ArriVent BioPharma shares are owned by institutional investors. 5.6% of Rhythm Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community believe in RYTM or AVBP? Rhythm Pharmaceuticals received 283 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 67.42% of users gave Rhythm Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRhythm PharmaceuticalsOutperform Votes30067.42% Underperform Votes14532.58% ArriVent BioPharmaOutperform Votes17100.00% Underperform VotesNo Votes Does the media prefer RYTM or AVBP? In the previous week, Rhythm Pharmaceuticals had 15 more articles in the media than ArriVent BioPharma. MarketBeat recorded 23 mentions for Rhythm Pharmaceuticals and 8 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.40 beat Rhythm Pharmaceuticals' score of 0.24 indicating that ArriVent BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral ArriVent BioPharma 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate RYTM or AVBP? Rhythm Pharmaceuticals presently has a consensus price target of $68.27, indicating a potential upside of 30.29%. ArriVent BioPharma has a consensus price target of $38.00, indicating a potential upside of 72.49%. Given ArriVent BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe ArriVent BioPharma is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rhythm Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91ArriVent BioPharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryArriVent BioPharma beats Rhythm Pharmaceuticals on 9 of the 14 factors compared between the two stocks. Get ArriVent BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVBP vs. The Competition Export to ExcelMetricArriVent BioPharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$742.35M$7.21B$5.81B$8.43BDividend YieldN/A2.79%4.76%3.97%P/E RatioN/A6.1524.9419.24Price / SalesN/A187.68376.51110.22Price / CashN/A65.6738.0534.58Price / Book-4.606.447.374.28Net Income-$69.33M$139.03M$3.18B$247.04M7 Day Performance-12.68%-3.52%-2.91%-3.25%1 Month Performance-21.85%-9.24%-6.80%-6.55%1 Year Performance-3.16%-12.95%12.66%4.01% ArriVent BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVBPArriVent BioPharma1.4736 of 5 stars$22.03-6.7%$38.00+72.5%+5.2%$742.35MN/A0.0040Earnings ReportNews CoveragePositive NewsHigh Trading VolumeRYTMRhythm Pharmaceuticals4.0825 of 5 stars$54.66-2.5%$68.09+24.6%+19.9%$3.36B$112.53M-12.62140Earnings ReportAnalyst ForecastVKTXViking Therapeutics4.4556 of 5 stars$29.20-14.3%$97.29+233.2%-69.8%$3.25BN/A-29.2020ACADACADIA Pharmaceuticals4.5795 of 5 stars$19.48-2.4%$24.00+23.2%-24.4%$3.24B$929.24M24.97510Analyst RevisionNews CoverageMRUSMerus3.0178 of 5 stars$46.75-1.3%$85.92+83.8%-12.3%$3.20B$35.93M-11.8437Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionMTSRMetseraN/A$29.81-5.8%N/AN/A$3.07BN/A0.0081DNLIDenali Therapeutics4.3832 of 5 stars$20.67-0.3%$37.42+81.0%-27.1%$2.97B$330.53M-7.49430Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageXENEXenon Pharmaceuticals1.8226 of 5 stars$38.37-3.4%$57.38+49.5%-23.6%$2.93B$9.43M-13.61210Earnings ReportAnalyst RevisionNews CoverageMORMorphoSys0.12 of 5 stars$18.96flat$18.25-3.7%N/A$2.86B$238.28M-5.45730HCMHUTCHMED1.7074 of 5 stars$15.40-4.4%$19.00+23.4%+5.0%$2.68B$610.81M0.001,988Gap DownBHCBausch Health Companies3.0599 of 5 stars$7.18-1.8%$7.42+3.4%-27.5%$2.64B$9.63B-59.7920,270 Related Companies and Tools Related Companies Rhythm Pharmaceuticals Competitors Viking Therapeutics Competitors ACADIA Pharmaceuticals Competitors Merus Competitors Metsera Competitors Denali Therapeutics Competitors Xenon Pharmaceuticals Competitors MorphoSys Competitors HUTCHMED Competitors Bausch Health Companies Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AVBP) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredLeaked Trump video exposes his secret stocksTen investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the polici...Porter & Company | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArriVent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
